Human PHAP Synthetic Peptide | Invitrogen PEP-0143 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human PHAP Synthetic Peptide

catalog :

PEP-0143

quantity :

50 ug

price :

US 167.00

product information

Product Type :

Peptide

Product Name :

Human PHAP Synthetic Peptide

Catalog # :

PEP-0143

Quantity :

50 ug

Price :

US 167.00

Clonality :

Synthetic

Purity :

purified

Reactivity :

Human

Applications :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Species :

Human

Storage :

-20 C

Description :

Apoptosis is related to many diseases and development. Caspase-9 plays a central role in cell death induced by a variety of apoptosis activators. Cytochrome c, after released from mitochondria, binds to Apaf-1, which forms an apoptosome that in turn binds to and activate procaspase-9. Activated caspase-9 cleaves and activates the effector caspases (caspase-3, -6 and -7), which are responsible for the proteolytic cleavage of many key proteins in apoptosis. The tumor suppressor putative HLA-DR-associated proteins (PHAPs) were recently identified as important regulators of mitochondrion apoptosis. PHAP appears to facilitate apoptosome-medicated caspase-9 activation and to stimulate the mitochondrial apoptotic pathway. PHAP was also shown to oppose both Ras- and Myc-medicated cell transformation.

Format :

Liquid

Applications w/Dilutions :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Aliases :

2410015B15Rik; 2810018A15Rik; Acid nuclear phosphoprotein 32 (leucine rich); acidic (leucine-rich) nuclear phosphoprotein 32 family, member A; acidic (leucine-rich) nuclear phosphoprotein 32 family, member B; acidic (leucine-rich) nuclear phosphoprotein 32 family, member D; acidic (leucine-rich) nuclear phosphoprotein 32 family, member E; acidic leucine-rich nuclear phosphoprotein 32 family member A; Acidic leucine-rich nuclear phosphoprotein 32 family member B; acidic leucine-rich nuclear phosphoprotein 32 family member E; acidic nuclear phosphoprotein 32; acidic nuclear phosphoprotein 32 family member A; acidic nuclear phosphoprotein 32 family member B; acidic nuclear phosphoprotein 32 family member E; acidic nuclear phosphoprotein 32 family, member A; acidic nuclear phosphoprotein 32 family, member B; acidic nuclear phosphoprotein pp32; Acidic protein rich in leucines; AI047746; AI326868; Anp32; Anp32a; Anp32b; ANP32D; ANP32E; APRIL; C15orf1; cerebellar leucine rich acidic nuclear protein; cerebellar postnatal development protein 1; Cpd1; hepatopoietin Cn; HPPCn; hypothetical protein LOC509685; I1PP2A; inhibitor-1 of protein phosphatase-2A; LANP; LANPL; LANP-L; LANP-like protein; Leucine-rich acidic nuclear protein; leucine-rich acidic nuclear protein LANP; leucine-rich acidic nuclear protein like; MAPM; Mapmodulin; mLANP-L; Pal31; PHAP1; PHAPI; PHAPI2; PHAPI2a; Potent heat-stable protein phosphatase 2A inhibitor I1PP2A; PP32; proliferation related acidic leucine rich protein PAL31; proliferation-related acidic leucine-rich protein PAL31; Putative HLA-DR-associated protein I; putative HLA-DR-associated protein I-2; putative human HLA class II associated protein I; silver-stainable protein SSP29; SSP29; vacidic (leucine-rich) nuclear phosphoprotein 32 family, member A; W91701